Acquisition by Lindsay Rosenwald of 10000 shares of Journey Medical at 3.04 subject to Rule 16b-3
| FBIOP Preferred Stock | USD 6.98 0.03 0.43% |
Slightly above 61% of Fortress Biotech's investor base is looking to short. The analysis of overall sentiment of trading Fortress Biotech Pref preferred stock suggests that many investors are alarmed at this time. Fortress Biotech's investing sentiment overview a quick insight into current market opportunities from investing in Fortress Biotech Pref. Many technical investors use Fortress Biotech Pref preferred stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Fortress |
Filed transaction by Journey Medical Corp Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Fortress Biotech Fundamental Analysis
We analyze Fortress Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fortress Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fortress Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Fortress Biotech is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Fortress Biotech Pref Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Fortress Biotech preferred stock to make a market-neutral strategy. Peer analysis of Fortress Biotech could also be used in its relative valuation, which is a method of valuing Fortress Biotech by comparing valuation metrics with similar companies.
Peers
Fortress Biotech Related Equities
| APTO | Aptose Biosciences | 5.56 | ||||
| KOD | Kodiak Sciences | 1.19 | ||||
| INDP | Indaptus Therapeutics | 0.99 | ||||
| RZLT | Rezolute | 1.08 | ||||
| FBIO | Fortress Biotech | 2.51 | ||||
| ACHL | Achilles Therapeutics | 2.94 | ||||
| CKPT | Checkpoint Therapeutics | 3.42 | ||||
| TPST | Tempest Therapeutics | 3.61 | ||||
| MBIO | Mustang Bio | 5.00 | ||||
| RVPH | Reviva Pharmaceuticals | 5.78 |
Additional Tools for Fortress Preferred Stock Analysis
When running Fortress Biotech's price analysis, check to measure Fortress Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fortress Biotech is operating at the current time. Most of Fortress Biotech's value examination focuses on studying past and present price action to predict the probability of Fortress Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fortress Biotech's price. Additionally, you may evaluate how the addition of Fortress Biotech to your portfolios can decrease your overall portfolio volatility.